Is Mesoblast Stock a Good Investment?

Mesoblast Investment Advice

MESO

To provide specific investment advice or recommendations on Mesoblast stock, we recommend investors consider the following general factors when evaluating Mesoblast. This will help you to make an informed decision on whether to include Mesoblast in one of your diversified portfolios:

Examine Mesoblast's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Mesoblast's leadership team and their track record. Good management can help Mesoblast navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Biotechnology space and any emerging trends that could impact Mesoblast's business and its evolving consumer preferences.
Compare Mesoblast's performance and market position to its competitors. Analyze how Mesoblast is positioned in terms of product offerings, innovation, and market share.
Check if Mesoblast pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Mesoblast's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Mesoblast stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Mesoblast is a good investment.

Sell

Buy

Cautious Hold

Our investment recommendation tool can cross-verify current analyst consensus on Mesoblast and to analyze the entity potential to grow in the current economic cycle. To make sure Mesoblast is not overpriced, please verify all Mesoblast fundamentals, including its ebitda, earnings per share, net asset, as well as the relationship between the debt to equity and total asset . Given that Mesoblast has a price to earning of (5.90) X, we recommend you to check Mesoblast market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your last-minute risk tolerance and investing horizon.

Market Performance	Very Weak	Details
Volatility	Somewhat reliable	Details
Hype Condition	Under hyped	Details
Current Valuation	Undervalued	Details
Odds Of Distress	Low	Details
Economic Sensitivity	Almost mirrors the market	Details
Investor Sentiment	Interested	Details
Analyst Consensus	Strong Buy	Details
Financial Strenth (F Score)	Poor	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Unlikely Manipulator	Details

Examine Mesoblast Stock

Researching Mesoblast's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was now reported as 0.42. The company recorded a loss per share of 1.05. Mesoblast had not issued any dividends in recent years. The entity had 1:2 split on the 10th of January 2024.

To determine if Mesoblast is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mesoblast's research are outlined below:

	Mesoblast generated a negative expected return over the last 90 days
	Mesoblast has high historical volatility and very poor performance
	The company reported the previous year's revenue of 5.9 M. Net Loss for the year was (87.96 M) with loss before overhead, payroll, taxes, and interest of (47.42 M).
	Mesoblast currently holds about 85.5 M in cash with (48.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62.
	Mesoblast has a poor financial position based on the latest SEC disclosures
	Latest headline from news.google.com: FDA approval remains Holy Grail for Aussie biotechs - NT News

Mesoblast Quarterly Good Will

134.45 Million

Mesoblast uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mesoblast. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mesoblast's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	26th of February 2024 Upcoming Quarterly Report	View
	23rd of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	4th of September 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	30th of June 2023 Last Financial Announcement	View

Earnings surprises can significantly impact Mesoblast's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Mesoblast's investors have experienced.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2023-02-27	2022-12-31	-0.1802	-0.1574	0.0228	12
2022-05-31	2022-03-31	-0.13	-0.16	-0.03	23
2020-05-27	2020-03-31	-0.17	-0.14	0.03	17
2020-02-26	2019-12-31	-0.2	-0.23	-0.03	15
2016-11-14	2016-09-30	-0.29	-0.26	0.03	10
2023-05-25	2023-03-31	-0.17	-0.13	0.04	23
2022-11-22	2022-09-30	-0.16	-0.12	0.04	25
2021-11-24	2021-09-30	-0.13	-0.17	-0.04	30

Know Mesoblast's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Mesoblast is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mesoblast backward and forwards among themselves. Mesoblast's institutional investor refers to the entity that pools money to purchase Mesoblast's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Rockbridge Investment Management, Llc	2024-12-31	49.1 K
Oaktree Fund Advisors, Llc	2024-12-31	47.9 K
Lpl Financial Corp	2024-12-31	38.9 K
Cubist Systematic Strategies, Llc	2024-12-31	35.2 K
Creative Planning Inc	2024-12-31	24.9 K
Pine Valley Investments Ltd Liability Co	2024-12-31	20.9 K
Geode Capital Management, Llc	2024-12-31	18.2 K
Thoroughbred Financial Services, Llc	2024-12-31	17.1 K
Wells Fargo & Co	2024-12-31	15.2 K
Blackrock Inc	2024-12-31	727.3 K
Morgan Stanley - Brokerage Accounts	2024-12-31	402.4 K

Note, although Mesoblast's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Mesoblast's market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.14 B.

Market Cap

1.26 Billion

Mesoblast's profitablity analysis

	Last Reported	Projected for Next Year
Return On Tangible Assets	(1.08)	(1.14)
Return On Capital Employed	(0.14)	(0.13)
Return On Assets	(0.13)	(0.12)
Return On Equity	(0.16)	(0.17)

Determining Mesoblast's profitability involves analyzing its financial statements and using various financial metrics to determine if Mesoblast is a good buy. For example, gross profit margin measures Mesoblast's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mesoblast's profitability and make more informed investment decisions.

Evaluate Mesoblast's management efficiency

Mesoblast has return on total asset (ROA) of (0.0541) % which means that it has lost $0.0541 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1791) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of March 2025, Return On Tangible Assets is likely to drop to -1.14. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Mesoblast's Other Current Assets are very stable compared to the past year. As of the 20th of March 2025, Total Current Assets is likely to grow to about 116.5 M, while Total Assets are likely to drop about 583.1 M.

	Last Reported	Projected for Next Year
Book Value Per Share	0.44	0.53
Tangible Book Value Per Share	(0.11)	(0.12)
Enterprise Value Over EBITDA	(11.46)	(12.04)
Price Book Value Ratio	1.58	1.50
Enterprise Value Multiple	(11.46)	(12.04)
Price Fair Value	1.58	1.50
Enterprise Value	821.4 M	1.2 B

Leadership at Mesoblast emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.

Beta

2.34

Basic technical analysis of Mesoblast Stock

As of the 20th of March, Mesoblast secures the Mean Deviation of 4.41, risk adjusted performance of 0.0686, and Downside Deviation of 4.34. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mesoblast, as well as the relationship between them.

Mesoblast's Outstanding Corporate Bonds

Mesoblast issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mesoblast uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mesoblast bonds can be classified according to their maturity, which is the date when Mesoblast has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

AerCap Global Aviation Corp Bond

US00773HAA59

View

View All Mesoblast Corporate Bonds

Understand Mesoblast's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Mesoblast's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	0.0686
	Market Risk Adjusted Performance	0.4738
	Mean Deviation	4.41
	Semi Deviation	4.23
	Downside Deviation	4.34
	Coefficient Of Variation	1471.88
	Standard Deviation	7.12
	Variance	50.7
	Information Ratio	0.0801
	Jensen Alpha	0.5728
	Total Risk Alpha	1.26
	Sortino Ratio	0.1315
	Treynor Ratio	0.4638
	Maximum Drawdown	49.53
	Value At Risk	(7.69)
	Potential Upside	13.29
	Downside Variance	18.84
	Semi Variance	17.86
	Expected Short fall	(6.09)
	Skewness	2.54
	Kurtosis	10.52

	Risk Adjusted Performance	0.0686
	Market Risk Adjusted Performance	0.4738
	Mean Deviation	4.41
	Semi Deviation	4.23
	Downside Deviation	4.34
	Coefficient Of Variation	1471.88
	Standard Deviation	7.12
	Variance	50.7
	Information Ratio	0.0801
	Jensen Alpha	0.5728
	Total Risk Alpha	1.26
	Sortino Ratio	0.1315
	Treynor Ratio	0.4638
	Maximum Drawdown	49.53
	Value At Risk	(7.69)
	Potential Upside	13.29
	Downside Variance	18.84
	Semi Variance	17.86
	Expected Short fall	(6.09)
	Skewness	2.54
	Kurtosis	10.52

Consider Mesoblast's intraday indicators

Mesoblast intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mesoblast stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	14960.82
	Daily Balance Of Power	0.5507
	Rate Of Daily Change	1.03
	Day Median Price	13.37
	Day Typical Price	13.42
	Price Action Indicator	0.36
	Period Momentum Indicator	0.38
	Relative Strength Index	40.56

Mesoblast Corporate Filings

6K	14th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.	View Verify
	12th of February 2025 Other Reports	View Verify
	6th of February 2025 Other Reports	View Verify
	5th of February 2025 Other Reports	View Verify

Mesoblast time-series forecasting models is one of many Mesoblast's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mesoblast's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Mesoblast Stock media impact

Far too much social signal, news, headlines, and media speculation about Mesoblast that are available to investors today. That information is available publicly through Mesoblast media outlets and privately through word of mouth or via Mesoblast internal channels. However, regardless of the origin, that massive amount of Mesoblast data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of Mesoblast news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Mesoblast relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Mesoblast's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Mesoblast alpha.

Mesoblast Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Mesoblast can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.

Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Mesoblast Maximum Pain Price Across April 17th 2025 Option Contracts

Mesoblast's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Mesoblast close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Mesoblast's options.

Mesoblast Corporate Management

LLB BCom	Joint Secretary	Profile
Justin BS	Head Manufacturing	Profile
Marcelo Santoro	Chief Officer	Profile
Roger BA	Head Disorders	Profile
Fiona See	Senior Research	Profile
MS MBA	Chief Officer	Profile
BSc LLB	Gen Exec	Profile

When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock: